The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status
10.3969/j.issn.1007-3969.2014.02.008
- VernacularTitle:18F-FES在乳腺癌患者体内摄取与病理免疫组化的关系
- Author:
Yifei SUN
;
Zhongyi YANG
;
Yongping ZHANG
;
Mingwei WANG
;
Zhifeng YAO
;
Jing XUE
;
Xiao BAO
;
Wentao YANG
;
Zhenzhou SHEN
;
Zhimin SHAO
;
Yingjian ZHANG
- Publication Type:Journal Article
- Keywords:
Estrogen receptor;
Immunohistochemistry;
18F-FES;
18F-FDG;
ER subtype
- From:
China Oncology
2014;(2):128-134
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:16α-[18F]lfuoroestradiol (18F-FES) is an in vivo speciifc imaging agent for estrogen receptor (ER). We investigated the concordance between tumor ER status as determined by FES-PET and in vitro immunohistochemical assays. Methods: 18F-FES was prepared by ourselves. Twenty-six patients were enrolled (17 primary and 9 metastatic/recurrent). Patients underwent both 18F-FES and 18F-FDG PET/CT. Results:We found good overall agreement (96.15%) between in vitro ER assays and FES-PET. The ER status diagnosis sensitivity of 18F-FES was 93.33%and the speciifcity was 100%when using cut-off value of SUVmax≥1.5. There was a positive correlation between in vitro ER, PR assays and the SUVmax of 18F-FES while in vitro HER-2/neu assays correlatived negatively with 18F-FES SUVmax. Conclusion:These results suggested 18F-FES may be useful for studying the ER expression of all malignant lesions in patients with breast cancer and guiding individual therapy.
